Novel bladder cancer treatment gains MHRA approval in the UK

Johnson & Johnson has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for BALVERSA®▼ (erdafitinib) as a monotherapy for the treatment of adults with unresectable or metastatic urothelial carcinoma (UC), the most common form of bladder cancer.

MHRA approves Pierre Fabre’s vibegron to treat OAB

The asset is indicated for the treatment of overactive bladder syndrome symptoms in adult patients. Credit: New Africa / Shutterstock. The UK Medicines and Healthcare

July 18, 2024

Cell and gene therapy biotechs face access hurdles in Europe – Pharmaceutical Technology

The BIO-Europe 2023 conference is currently ongoing in Munich, Germany. Image credit: Akosua Mireku While the number of cell and gene therapy approvals continues to

November 7, 2023

Abortion Ban Deaths; Trans Paper Retraction Fallout; The Payout That Drained Steward

Welcome to the latest edition of Investigative Roundup, highlighting some of the best investigative reporting on healthcare each week. Georgia Abortion Ban Linked to Two

September 19, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.